VYNE Therapeutics Beheer
Beheer criteriumcontroles 2/4
VYNE Therapeutics' CEO is Dave Domzalski, appointed in Mar 2020, has a tenure of 4.67 years. total yearly compensation is $2.72M, comprised of 23.5% salary and 76.5% bonuses, including company stock and options. directly owns 3.37% of the company’s shares, worth $1.32M. The average tenure of the management team and the board of directors is 4.7 years and 3.6 years respectively.
Belangrijke informatie
Dave Domzalski
Algemeen directeur
US$2.7m
Totale compensatie
Percentage CEO-salaris | 23.5% |
Dienstverband CEO | 4.7yrs |
Eigendom CEO | 3.4% |
Management gemiddelde ambtstermijn | 4.7yrs |
Gemiddelde ambtstermijn bestuur | 3.6yrs |
Recente managementupdates
Recent updates
We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate
Oct 09Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation
Apr 27We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate
May 04VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M
Aug 12Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky
Jul 02VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely
Mar 19VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan
Jan 13VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely
Dec 03Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13VYNE Therapeutics: Terrible Depreciation Of Shareholder Value
Jun 30Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt
Jun 07Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts
Feb 17Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)
Feb 10VYNE Therapeutics closes capital raise of $50M
Jan 29Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$28m |
Mar 31 2024 | n/a | n/a | -US$29m |
Dec 31 2023 | US$3m | US$638k | -US$28m |
Sep 30 2023 | n/a | n/a | -US$29m |
Jun 30 2023 | n/a | n/a | -US$33m |
Mar 31 2023 | n/a | n/a | -US$31m |
Dec 31 2022 | US$1m | US$638k | -US$34m |
Sep 30 2022 | n/a | n/a | -US$35m |
Jun 30 2022 | n/a | n/a | -US$40m |
Mar 31 2022 | n/a | n/a | -US$42m |
Dec 31 2021 | US$5m | US$638k | -US$44m |
Sep 30 2021 | n/a | n/a | -US$59m |
Jun 30 2021 | n/a | n/a | -US$69m |
Mar 31 2021 | n/a | n/a | -US$226m |
Dec 31 2020 | US$3m | US$501k | -US$256m |
Sep 30 2020 | n/a | n/a | -US$270m |
Jun 30 2020 | n/a | n/a | -US$269m |
Mar 31 2020 | n/a | n/a | -US$120m |
Dec 31 2019 | n/a | n/a | -US$95m |
Sep 30 2019 | n/a | n/a | -US$71m |
Jun 30 2019 | n/a | n/a | -US$64m |
Mar 31 2019 | n/a | n/a | -US$63m |
Dec 31 2018 | US$1m | US$440k | -US$74m |
Sep 30 2018 | n/a | n/a | -US$77m |
Jun 30 2018 | n/a | n/a | -US$80m |
Mar 31 2018 | n/a | n/a | -US$77m |
Dec 31 2017 | US$3m | US$417k | -US$66m |
Compensatie versus markt: Dave's total compensation ($USD2.72M) is above average for companies of similar size in the US market ($USD655.02K).
Compensatie versus inkomsten: Dave's compensation has increased whilst the company is unprofitable.
CEO
Dave Domzalski (57 yo)
4.7yrs
Tenure
US$2,716,350
Compensatie
Mr. David T. Domzalski, also known as Dave, has been President, Chief Executive Officer and Director at VYNE Therapeutics Inc. (formerly known as Menlo Therapeutics Inc.). since March 9, 2020. Mr. Domzalsk...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO, President & Director | 4.7yrs | US$2.72m | 3.37% $ 1.3m | |
Chief Scientific Officer | 4.7yrs | US$1.16m | 0.91% $ 353.8k | |
General Counsel | 4.7yrs | US$1.13m | 1.01% $ 394.9k | |
CFO & Treasurer | 3.4yrs | geen gegevens | 0.89% $ 348.7k | |
Senior Vice President of Clinical Development | less than a year | geen gegevens | geen gegevens | |
Consultant | 6yrs | US$115.20k | geen gegevens |
4.7yrs
Gemiddelde duur
51yo
Gemiddelde leeftijd
Ervaren management: VYNE's management team is considered experienced (4.7 years average tenure).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO, President & Director | 4.7yrs | US$2.72m | 3.37% $ 1.3m | |
Independent Non Employee Director | 4.7yrs | US$116.10k | 0.0071% $ 2.8k | |
Lead Independent Director | 4.2yrs | US$123.60k | 0.25% $ 96.7k | |
Director | 9.2yrs | US$83.60k | 0.051% $ 19.7k | |
Independent Non-Employee Director | 4.7yrs | US$101.10k | 0.013% $ 5.0k | |
Independent Director | 5.7yrs | US$108.60k | 0% $ 0 | |
Independent Director | less than a year | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | 3.1yrs | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | 3.1yrs | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | 3.1yrs | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | 3.1yrs | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | 3.1yrs | geen gegevens | geen gegevens |
3.6yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren bestuur: VYNE's board of directors are considered experienced (3.6 years average tenure).